RheumaGen
RheumaGen is a cell and gene therapy company developing curative treatments for autoimmune diseases. They focus on editing the human leukocyte antigen (HLA) to prevent the immune system from attacking healthy cells. Their lead program, RG0401, targets treatment-resistant rheumatoid arthritis.
Funding Round: Series A
Funding Amount: $15M
Date: 09-Jan-2025
Investors: SPRIM Global Investments, William Taylor Nominees
Markets: Cell and Gene Therapy, Autoimmune Diseases, Biotechnology, Genetics, Life Science
HQ: Denver, Colorado, United States
Founded: 2019
Website: https://rheumagen.com/
LinkedIn: https://www.linkedin.com/company/rheumagen
Crunchbase: https://www.crunchbase.com/organization/rheumagen
Leave a Comment
Comments
No comments yet.